IBRC - iBrands Corp

Our latest pick, iBrands Corporation, is looking like it’s ready to soar!
Here are a few bulletins on this company…
iBrands Corporation is revolutionizing the restaurant industry with their two subsidiaries, i Software, Inc. and iMenu24/7, Inc., both targeted to providing consumer online ordering and related technologies for the worldwide restaurant industry.
iSoftware, Inc. own all of the proprietary software for the Company. i Software has been organized to provide the Company economies of scale of Internet technology, programmers, web designers and related technical services. i Software’s goal is to minimize overhead expenses and attains to outsource most of its technical requirements. Our state-of-the-art server farm is located in Atlanta and is maintain by ThinLine IT Services, www.thinlineit.com, with access to unlimited bandwidth.
iMenu24/7 is the brand name for our consumer online ordering targeted to the worldwide restaurant industry. iMenu24/7 also is our marketing company targeting the restaurateur, whether they are a single unit owner or a multi-unit chain. The industry in North America has over 1.1 million restaurants generating $617 Billion in annual revenues comprising of 45.2 billion meals ordered for off-premises (“take out” orders). According to the National Restaurant Association, less than 5% of restaurants in North America currently have online order capabilities. iMenu24/7 has processed over 1.5 million orders for its customers over the past several years.
For more information, visit their website at http://www.ibrandscorp.com



Don’t miss out on this great investment opportunity, and remember where you heard it first – http://www.TheStockCents.com



Be sure to read our Disclaimer at http://www.TheStockCents.com/Disclaimer.html

PASO - Public Access Solutions, Inc.

Patient Access Solutions, INC - PASO


Everyone keeps asking us when our next pick will be coming out, well here it is.

Patient Access Solutions, Inc - (PASO)

Paying little respect to tradition in a business rooted in tradition, PASHealth has created a formidable array of technology, resources and allies to enable it to become an agent of radical change in what has traditionally been a slowly evolving healthcare environment, and for that reason, PASO - PasHealth is a rapidly growing company in the healthcare industry.

Providing a wide variety of services for the medical field, there is no wonder why we think PASHealth could be a great investment.


Services Provided:



D-PAS Technology
Digital pen & paper, a component of Anoto technology, to capture handwritten information


Claims Analyzer
The entire process is 100% paperless, secure and takes about 45 seconds to complete


Payment Processing
Turnkey payment service solutions for the receipt of patient self pay receivables



Eligibility
PASHealth POS terminal and web portal enables the payer's office to access information via a swipe card or a data entry procedure


PAS Prescription Center
Increase productivity, reduce costs and provide patients the best possible care


Resources
View videos, audio, and
PDF presentations from PASHealth



Electronic Medical Records & Patient Health Records
PASHealth makes it simple... Just use a Pen and Paper!


Services By Industry
Medical, Dental, Chiropractic, and Veterinary Services


Mobipen
Together with Catrel AB delivering solutions for the home healthcare industry



For more information take a look at their website at http://www.pashealth.com.

Recent News:

OHEL Children's Services Launches Patient Access Solutions' Mobipen Pilot Program to Handle Caregivers Paperwork

HAUPPAUGE, N.Y., July 27, 2010 /PRNewswire via COMTEX/ -- Patient Access Solutions, Inc. (Pink Sheets: PASO), a leading provider of information technology solutions for the healthcare, homecare and dental industries is pleased to announce it has contracted with OHEL Children's Services Inc., to manage caregiver visits and additional services going forward using the Patient Access Solutions Mobipen digital pen application.
The solution, based on PASHealth's Mobipen digital pen technology, will pilot with 25 key users in the OHEL organization and expand to over 400 licensed users when fully implemented in Q4, 2010. Field workers will be able to process paperwork in their usual work flow, while concurrently being able to digitally transfer the information back to the OHEL Children's Services' main office using the robust form capture infrastructure to interface patient data and caregiver digital note application.

According to Bruce Weitzberg, CEO and President of Patient Access Solutions, "We look forward to implementing the Mobipen application to help improve the efficiency and reporting needs of OHEL Children's Services. The advantages of streamlining the client's paper process while improving productivity and providing an operational cost savings were obvious. The company's Mobipen application currently retails at $89.95 per licensed full-time user per month."

About OHEL Children's Home and Family Services

The mission of OHEL Children's Home and Family Services, established in 1969, is to protect and strengthen individuals and families by meeting the diverse social service needs of the community through programs of excellence. Uniquely culturally sensitive to the particular needs of the Jewish population, OHEL serves communities in New York City, the surrounding Boroughs, Northern New Jersey, Southern Florida and worldwide on the web. OHEL is driven to constantly supersede all professional and regulatory standards. Leveraging OHEL's experience and reputation, we seek to proactively identify community social challenges by pioneering new programs that elevate the lives of individuals and families every day.

About Patient Access Solutions, Inc.

Patient Access Solutions, Inc. (PAS) is a Healthcare Solutions Company which has created a formidable array of technology, resources and allies to enable it to become an agent of radical change in what has traditionally been a slowly evolving healthcare information technology environment. The Company's products are designed to allow health care providers an easy migration to the EMR environment. Among these products are D-PAS, which is a state-of-the-art digital pen and paper technology based on Anoto technology, used to capture hand written information into digital forms and EMR systems and PAS Data Center, which is a terminal solution that allows health care providers to quickly and easily determined benefit eligibility. More information on Patient Access Solutions, Inc. and its products can be viewed at www.pashealth.com.

Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the companies, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Factors that could cause actual results to differ materially from those in the forward-looking statements include, among other things, the following: general economic and business conditions; competition; unexpected changes in technologies and technological advances; ability to commercialize and manufacture products; results of experimental studies; research and development activities; changes in, or failure to comply with, governmental regulations; and the ability to obtain adequate financing in the future. This information is qualified in its entirety by cautionary statements and risk factors disclosure contained in certain of Patient Access Solutions Inc. Securities and Exchange Commission filings available at http://www.sec.gov.

Investor Information:

Joe Noel

Emerging Growth Research, LLC

925-922-2560

SOURCE Patient Access Solutions Inc.



www.prnewswire.com
Copyright (C) 2010 PR Newswire. All rights reserved
-0-

KEYWORD: New York
INDUSTRY KEYWORD: HEA
SUBJECT CODE: CON



Don't miss out on this great investment opportunity.



Disclaimer
http://www.TheStockCents.com/Disclaimer.html

STHG - Stratton Holdings, Inc.

Hello Traders,

We think this next pick could be a great one!

STHG - Stratton Holdings, Inc.

Stratton Holdings, Inc. was formed in 2008 with the overall mission of seeking out small to mid-sized companies to bring to the Stratton Holdings, Inc. family and assist in their expansion and in turn use those profits to repeat the cycle creating value and products worth being proud of.

A majority of the time a restructuring of the company is executed to reduce costs and increase sales and revenue. The Company is constantly seeking out exciting opportunities.

Stratton Holdings, Inc. specializes in the following fields:


* Real Estate
* Publishing
* E-commerce
* Security Investments
* Wireless Technology
* Sales Management
* Administration Technology


Question and Answer Session
On Friday January 23rd 2009 a Question and Answer Session was held with CEO Eric Stratton Racheff and CFO Clayton A. Adler. They went over the goals of the company and the most commonly asked questions by shareholders, We called this stock at $0.003 two days ago and it's already hit $0.0085 and still rising!

Don't miss out on this great investment opportunity!

Good luck & happy trading!

HBRM ! LOOKING GOOD !

Hello Traders,
We think this next pick could be a great one!
HBRM - Herborium Group, Inc.
Investor Relations
HERBORIUM Inc. is a New Jersey based company incorporated in the State of Delaware in the year 2000, which offers unique and proprietary herbaceuticals supported by clinical experience and the innovative use of interactive information technology.

HERBORIUM is an industry innovator offering what constitutes a Complete Alternative Medicine Solution. Our goal is to attract, coach and maintain high-involvement and high enduring clients in both organizational and consumer markets. Our tool is the intense use of proprietary and superior products, and the application of interactive and customized strategies with targeted content and delivery.

HERBORIUM is not a nutraceutical distributor but rather a botanical therapeutics company providing proprietary all natural, herbaceuticals that address unmet health care needs. The company retains exclusive marketing rights to the US and EU markets and is presently pursuing an intellectual property position in the area of dermatology, urology and sexual health, liver disease and women health. The Company uses clinical validation of its products and a proactive approach to a regulatory strategy to establish and maintain its differential advantage. HERBORIUM manufactures its herbal-based products according to pharmaceutical standards, assuring quality, consistency, and clinical effectiveness.

The company employs Health Care Information Technology to empower its customer and consumer base to make informed medical and self-medication decisions. HERBORIUM's products are currently regulated by DSHEA 94, which affords immediate market access, translating into near term revenues and markedly reduced risk.

HERBORIUM's business model is also supported by the newly emerging opportunities afforded by the changing FDA perspectives with respect to botanical drugs. The company has developed preliminary collaborative relationships with proactive medical institutions in the US, Europe and Asia to capitalize on this opportunity.

The Company approach reflects composite innovation in both healthcare and information technology areas. HERBORIUM's product line and near term pipeline are solely based on products whose IP is patent or Trade Secret protected. The Company's innovative and customized use of IT to provide a total alternative medical solution sets a Company apart and ahead of the competition. The focus on information ties directly to The Health Care Distribution Management Association (HDMA) analysis listing the advent of the Internet and broad accessibility to IT technology as major forces shaping the healthcare industry. The company's use of HealthCare Information Technology (HCIT) harnesses the connectivity needed to penetrate both the consumer and organizational markets. This positions HERBORIUM to become the destination of choice for end-users and healthcare professionals alike seeking alternative answers to disease treatment, management and prevention.

HERBORIUM's business opportunity stems from the growing need for alternative approaches to the treatment and prevention of diseases and specific common health concerns in the United States and international markets. The market areas targeted by HERBORIUM offer substantial revenue potential and competitive advantages over Western Medicine. The global market for alternative medicinal products including herbaceuticals is 3 trillion USD with over $28 billion spent in the US in 2005.

The Company has assembled a highly qualified management team complimented by a versatile experienced group of professional consultants. The Company has recruited affiliates and/or partners in the US and abroad which support its mission and operation with their collective expertise. This organization allows the Company to respond efficiently to the changing demands of the business and market environment, minimizes costs and provides for efficient risk management.

Hello, Traders.
Every now and again, trade opportunities come across my desks and my sense of excitement begins to rise
...my pupils begin to expand
...my palms begin to sweat
...and, my heart beats a little faster.
It's because my intuition is telling me that I could be onto something with more potential than most trade ideas I'v seen in many days...possibly many weeks.
Now, that's the type of stock I could be introducing to you TODAY!

-------------------------------------------------------------

My Next Huge Biotech Stock is...

*** Echo Therapeutics (OTCBB: ECTE) ***



Echo Therapeutics is a transdermal medical device company developing its needle-free Symphony™ tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and its Prelude™ SkinPrep System as a platform technology for transdermal drug delivery.

ECTE believes that the Symphony tCGM System will change the paradigm of invasive, needle-based, pisodic glucose testing in the diabetes consumer and hospital critical care markets to one of continuous, eedle-free monitoring.

ECTE is also developing its needle-free Prelude SkinPrep System as a platform technology for enhanced skin permeation to allow for transdermal drug delivery of a wide range of FDA-approved products.
ECTE believes that the Symphony system is an ideal solution for diabetics and critically ill patients allowing for continuous, pain-free monitoring of glucose levels.

The continuous monitoring will enable more accurate management of diabetes (resulting in healthier outcomes) and higher compliance compared to painful, invasive methods for drawing blood today.

ECTE also believes that its Prelude SkinPrep System will allow many drugs currently delivered by needle injection to be administered without a needle by using Prelude prior to transdermal drug administration.

----------------------------------
ECTE's $15 Million Agreement


ECTE has signed a $15 million agreement, giving Ferndale Pharmaceuticals a license to develop, market and sell Prelude for enhanced delivery of Ferndale’s topical lidocaine product, LMX4, in North America and the UK. Echo received $750,000 up front and will receive $750,000 upon FDA approval, as well as $12.5 million in milestones and guaranteed minimum royalty payments. Echo will also receive a double digit royalty on
net sales of the product.

------------------------------------------------
What is the Symphony™ tCGM System?



Non-invasive, wireless, continuous blood glucose monitoring system
Utilizes Prelude™ SkinPrep, a novel, needle-free platform technology that increases skin permeability
Efficient, remote monitoring platform compared to platforms using needle-basedtechnologies for accuracy
Low manufacturing cost and a razor/razor blade model with a single-use consumable
Readings obtained every minute with wireless data transmission to portable monitor
Short, one-hour warm-up
----------------------------------------------------


Product Pipeline


Six consecutive positive pilot studies in glucose monitoring to date
510-k filing in 1Q10 for Prelude with the use of lidocaine
Prelude lidocaine sales offer best near-term revenue opportunity
Minimum sales would reduce cash burn and move company toward cash flow positive business
Revenues projected to begin during 2Q10
Pivotal trial and PMA filing for Symphony™ anticipated in 2010 for glucose monitoring
Symphony™ tCGM licensed in South Korea to Handok Pharmaceuticals
---------------------------------------------

ECTE Could Be a High Growth Top-Shelf Pharmaceutical/Biotech Stock


I've mentioned that there are some stocks that perform extremely well because they are "Story Stocks" whose one-of-a-kind, unique technology is intriguing and special enough that it makes entertaining discussions for those not even involved in development-stage companies that are abundant in the OTC/OTCBB Markets.
And, there are other stocks that have highly compelling reasons from a technical viewpoint that suggest a profitable breakout could put traders into outstanding profit positions.
So, how does this relate to Echo Therapeutics (OTCBB: ECTE)? Simple...I believe that ECTE has both categories of trading philosophies in its corner, and that could be the ingredients for an explosive opportunity wherein the symbol could absolutely soar!

Watch ECTE trade...don't miss out!






Best Regards,

StockAlert@TheStockCents.com

www.TheStockCents.com

kcmh

Happy New Year!


This is a great day to be in the market! There are a lot of people on vacation right now but those that have stuck around to trade and invest are poised to potentially make some great returns once everyone is back next week.



We would like to introduce a little technical analysis lesson which I believe applies very well here.



This is an example of a Rounding Bottom which KCMH weekly chart is also displaying. This shows what the potential of KCMH could be!


(use roundingbot-example)
(use kcmhdec30weekly)





News came out this morning that shows that this move is just beginning!


Here are some of the highlights from PR.....

KCM HOLDINGS CORP. RECEIVES 2009 BEST OF BUSINESS AWARD
STILL DEBT-FREE & PROFITABLE - KCMH has remained debt free and profitable every quarter since its inception in 2007.
MARKETPLACE – The stock is starting to gain recognition and visibility in the marketplace. They anticipate increased volume, price-per-share, and a $100M+ market cap in 2010.
GEENIUS - Will be publicly trading in 1st Quarter 2010. KCMH owns 10% plus revenue sharing. The Geenius IPO will increase KCMH’s book value by millions of dollars.
EMPIRE RECORDINGS - Will be distributed by a major industry label to be announced on the near term horizon. Kevin Alexander, President and CEO, brings over 15 years of music experience, working with the biggest acts in the industry such as: The Black Eyed Peas, G-Unit, Dr. Dre, Eryka Badu, Eminem and Linkin Park.
KCM INSURANCE SERVICES – They expanded their already successful insurance division to include mortgage protection insurance coverage. 2010 gross revenue projections are between $5 and $6 million dollars.
CONTINUED DEVELOPMENT & COMMITMENT - They are committed to safeguarding the KCMH capital structure and increasing shareholder value and will continue to maintain that commitment indefinitely. They are currently in negotiations to add an alternative energy company and a custom motorcycle manufacturer to the KCMH portfolio.
PINKSHEETS - In late December KCMH was downgraded from "Current Information" Status to "Limited Information". They will have a legal opinion letter for 4Q 2009 submitted in early January 2010, and will return to "Current Information."
We wish everyone a very HAPPY NEW YEAR and MANY HAPPY RETURNS!